Please ensure Javascript is enabled for purposes of website accessibility

Is Johnson & Johnson a Buy?

By Zhiyuan Sun - Mar 10, 2021 at 6:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are better reasons for investing in Johnson & Johnson than its coronavirus vaccine.

It may be surprising to hear that coronavirus vaccine maker Johnson & Johnson (JNJ 0.91%) has significantly underperformed the market over the past year. Indeed, during that period, the pharma giant's stock only went up a meager 12%, far less than the S&P 500 index's mouth-watering 30% gain. This has left many investors wondering: Why?

As it turns out, the golden age of investing in coronavirus vaccine stocks is mostly over. Now's the time for coronavirus vaccine manufacturers to show that they can turn reliable profits with what they developed. Can Johnson & Johnson accomplish that goal?

Man holding coronavirus vaccine record and flashing a thumbs-up

Image source: Getty Images.

Get excited about the stock, not the vaccine

Investors new to Johnson & Johnson are arguably most enthusiastic about its coronavirus vaccine. During clinical testing, 85% of patients who received the vaccine became protected against severe cases of COVID-19. There were little to no serious side effects. The vaccine received Emergency Use Authorization (EUA) in the U.S. late last month.

The vaccine is appealing given that it requires only a single dose for adequate immunization. Johnson & Johnson has already received orders for 500 million doses, with the capacity to produce one billion doses this year. At a price tag of $10 per dose, that means the company could have up to $10 billion in potential revenue over the next two years.

However, it is important to note that Johnson & Johnson does not expect to profit from this venture. That means while its vaccine will have a material impact on its revenue, it will not change its bottom line this year. Because the promise is gratuitous (like giving a gift without asking anything in return), however, Johnson & Johnson is under no obligation to supply its vaccine at break-even levels and could very well charge a profit in the future.

That said, Johnson & Johnson is a great stock to buy purely for its core business strength. Last year, the company's consumer health, medical devices, and pharmaceutical segments brought a combined $82.6 billion in revenue, up 0.6% over 2019. The COVID-19 pandemic led to the deferral of many elective procedures and discretionary medical apparatus spending. As a result, the pharma giant's earnings per share (EPS) declined by 7.5% year over year to $8.03.

This year, however, Johnson & Johnson expects to rebound sharply. It is forecasting annual revenue and EPS of $91.7 billion and $9.50, respectively. The company has five phase 3 clinical data readouts on the way for therapeutics that target Crohn's disease, schizophrenia, leukemia, COVID-19, and prostate cancer. It also has nine potential drug approvals in the same period. There are approximately 50 therapeutic candidates in Johnson & Johnson's pipeline ranging from neuroscience to oncology.

One key thing driving Johnson & Johnson's growth is its commitment to research and development. In 2020, it spent over $12 billion in that area. Alongside the commitment, the company still paid $10.5 billion in dividends to shareholders. Its stock currently has an annual dividend yield of 2.6%.

What's the verdict?

Right now, the average pharma stock trades for 4.9 times revenue and 34 times earnings. Johnson & Johnson stock is a little cheaper at five times sales and 21 times free cash flow. Given its robust guidance, outstanding pipeline, and solid dividend yield, this is definitely a top pharma stock to add to your portfolio.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$181.09 (0.91%) $1.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.